Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma - Summary - MDSpire

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • By

  • Kevin Charles Miller

  • Patrick Connor Johnson

  • Jeremy S. Abramson

  • Jacob D. Soumerai

  • Andrew J. Yee

  • Andrew R. Branagan

  • Elizabeth K. O’Donnell

  • Anna Saucier

  • Caron A. Jacobson

  • Matthew J. Frigault

  • Noopur S. Raje

  • November 1, 2022

  • 0 min

Share

Objective:

To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on the toxicities associated with CAR T cell therapy for lymphoma and multiple myeloma, focusing on its potential implications for patient management.

Key Findings:
  • G-CSF administration's impact on CRS and ICANS remains unclear.
  • High serum G-CSF levels are associated with severe ICANS.
  • Most institutions lack a standardized approach for G-CSF use in CAR T patients, highlighting the need for consensus.
Interpretation:

The study highlights the need for further investigation into G-CSF's role in managing post-CAR T toxicities, given its potential effects on myeloid cell activation and associated risks for exacerbating toxicities.

Limitations:
  • Retrospective design may introduce bias.
  • Limited sample size and variability in G-CSF administration practices may affect the generalizability of findings.
Conclusion:

Further prospective trials are warranted to establish clear guidelines for G-CSF use in CAR T therapy to enhance patient safety.

Original Source(s)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • by Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje

  • November 1, 2022

Related Content

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

Anatomy-aware lymphoma lesion detection in whole-body PET/CT

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min